GLP-1 medications remain one of the most popular weight loss drugs on the market, but new research suggests consistency may be key to maintaining their effectiveness. A recent study from the ...
Julia Sullivan is a health and fitness writer, editor and content strategist well as a certified personal trainer. Her byline is in many publications from Harper's Bazaar to SELF Magazine to brand ...
A federal judge blocked the Federal Trade Commission (FTC) from investigating the Endocrine Society and World Professional Association for Transgender Health, which support gender-affirming care in ...
Share on Pinterest The number of people getting bariatric surgery for weight loss has declined, partly due to the rise of GLP-1 medications. KARRASTOCK/Getty Images Until recently, bariatric surgery ...
A common side effect of many GLP-1 drugs is hair loss. It's creating a growing market for hair treatment products. Companies like Redken, Nutrafol and KeraFactor are leaning into the innovation and ...
The use of GLP-1 medications for weight loss continues to rise. One drawback associated with GLP-1 medications is that weight loss not only includes fat loss, but muscle loss as well. A new study ...
Hosted on MSN
FTC: Scammers make most money using social media
James details new findings from the Federal Trade Commission about how scammers are making money. Roberts and Kavanaugh just broke ranks in a 5-4 Supreme Court vote Mexican restaurant chain ends US ...
Americans lost at least $2.1 billion in 2025 to scams that originated on social media, according to the Federal Trade Commission. That figure marks an eightfold increase since 2020. The FTC said ...
The U.S. Federal Trade Commission (FTC) warned of a massive increase in losses from social media scams since 2020, exceeding $2.1 billion in 2025. According to reports to the FTC's Consumer Sentinel ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Compared with nonusers, people taking a GLP-1 had ...
Not too long ago I would have said I was one of the least likely people to be tempted by GLP-1s like Wegovy or Zepbound. My weight has always been average. I have no medical conditions, and more than ...
Employer cost coverage increases likelihood of GLP-1 use (65% overall), peaking in ages 35–44 (75%) and declining sharply among workers ≥65 (37%). Behavioral support programs shift willingness to self ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results